EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

CX3CR1 + CD8 + T cells: Key players in antitumor immunity

Jiajin Ma iD, Yue Wu, Shaoxian Wu, Zhang Fang, Lujun Chen, Jingting Jiang iD, Xiao Zheng

Cancer Science · 2024

DOI: 10.1111/cas.16359 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, 2024. Verfasst von Jiajin Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, CX3C Chemokine Receptor 1, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changzhou International Cooperation Project, the Key Project of Jiangsu Provincial Health Commission, the Key R&D Project of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CX3CR1 functions as the specific receptor for the chemokine CX3CL1, demonstrating expression across a broad spectrum of immune cells. This underscores its pivotal role in communication and response mechanisms within the immune system. Upon engagement with CX3CL1, CX3CR1 initiates a cascade of downstream signaling pathways that regulate various biological functions. In the context of tumor progression, the intricate and inhibitory nature of the tumor microenvironment presents a significant challenge to current clinical treatment techniques. This review aims to comprehensively explore the tumor‐destructive potential shown by CX3CR1 + CD8 + T cells. Simultaneously, it investigates the promising prospects of utilizing CX3CR1 in future tumor immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesCX3C Chemokine Receptor 1NeoplasmsTumor MicroenvironmentImmunotherapyHumansAnimalsChemokine CX3CL1Signal Transduction

Stichwörter der Autor:innen

CD8+ T cellCX3CR1immunotherapytumor microenvironment

Substanzen

CX3C Chemokine Receptor 1CX3CR1 protein, humanChemokine CX3CL1CX3CL1 protein, human

Autor:innen und Institutionen

  • Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
  • Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China.
  • Institute for Cell Therapy of Soochow University, Changzhou, China.

ORCID-Profile: Jiajin Ma, Jingting Jiang

Förderung

  • Changzhou International Cooperation Project
  • the Key Project of Jiangsu Provincial Health Commission
  • the Key R&D Project of Jiangsu Province
  • the Science and Technology Support Plan (Social Development) Project of Changzhou
  • National Natural Science Foundation of China
  • the Jiangsu Provincial Medical Key Discipline
  • Changzhou Medical Center of Nanjing Medical University

Zitieren

APA

Ma, J., Wu, Y., Wu, S., Fang, Z., Chen, L., Jiang, J., & Zheng, X. (2024). CX3CR1 + CD8 + T cells: Key players in antitumor immunity. Cancer Science. https://doi.org/10.1111/cas.16359

Vancouver

Ma J, Wu Y, Wu S, Fang Z, Chen L, Jiang J, et al. CX3CR1 + CD8 + T cells: Key players in antitumor immunity. Cancer Science. 2024. doi:10.1111/cas.16359

BibTeX
@article{Ma2024,
  author = {Ma, Jiajin and Wu, Yue and Wu, Shaoxian and Fang, Zhang and Chen, Lujun and Jiang, Jingting and Zheng, Xiao},
  title = {CX3CR1 + CD8 + T cells: Key players in antitumor immunity},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16359}
}
Kostenlos starten →